In the face of growing chloroquine resistance of Plasmodium falciparum, efforts to prolong the clinical usefulness of the drug have partly concentrated on its combination with potential resistance-reversing compounds. However, clinical studies on such combinations have been limited. We have compared
Comparative cardiac effects of halofantrine and chloroquine plus chlorpheniramine in children with acute uncomplicated falciparum malaria
โ Scribed by A. Sowunmi; F.A. Fehintola; O.A.T. Ogundahunsi; A.B. Ofi; T.C. Happi; A.M.J. Oduola
- Publisher
- Elsevier Science
- Year
- 1999
- Tongue
- English
- Weight
- 791 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0035-9203
No coin nor oath required. For personal study only.
โฆ Synopsis
The cardiac effects ofhalofantrine (HF) and chloroquine plus chlorpheniramine (CQ-CP), a histamine Hi antagonist which reverses chloroquine insensitivity in Plasmodium falciparum in vitro and in vivo, were assessed in 41 children with acute svmntomatic uncomnlicated P fa&arum malaria bv electrocardiographic and clinical monitoring over a-period of 14 days. gaddition, the cardiac effects of chioroquine (CQ) alone and CQ-CP were compared in 10 age-and sex-matched children. HF produced a significantly higher proportion of abnormally prolonged P-R interval (8 abnormally prolonged out of 132 total P-R events) than CQ-CP (1 of 133 P-Revents) (P = 0.03), but a similar proportion ofprolonged Q-Tc interval to that of CQ-CP (46 of 149 versus 29 of 134 events, P = 0.07). Compared with pre-treatment Q-Tc, HF significantly prolonged this interval from 6 to 96 h post treatment with a maximum effect at 24 h after commencing HF treatment. CQ-CP by contrast produced significant changes in Q-Tc values from 6 to only 48 h with a maximum effect at 48 h. HF-induced Q-Tc prolongations were significantly higher than those of CQ-CP only at 24 h. The cardiac effects of CQ-CP were similar to those of CQ alone. Despite the electrocardiogram abnormalities, rhythm disturbance was rare and there was no clinical symptom in any of the treatment groups. Compared with HF, CQ-CP produced cardiac effects that were less severe and in fewer children with acute falciparum malaria. The addition of CP to CQ does not significantly amplify the cardiac effects of CQ in children with acute uncomplicated falciparum malaria.
๐ SIMILAR VOLUMES
The efficacy of pyrimethamineisulfadoxine (I'S) and chloroquine plus chlorpheniramine, a histamine H1 receptor blocker which reverses chloroquine insensitivity in Plasmodium falciparum in vitro, was evaluated in 100 consecutive children with acute symptomatic uncomplicated falciparum malaria. Parasi
Chlorpheniramine, a histamine HI receptor antagonist, reverses chloroquine resistance in Plasmodium falciaarum in vitro. However. the clinical sianificance of this remains unclear. We have evaluated the efficacv of chloroquine and a chloroquine-chlorbheniramine combination in 112 consecutive childre
Chlorpheniramine (Cl'), a histamine Hi-receptor antagonist, enhances the efficacy of chloroquine (CQ) in acute uncomplicated falciparum malaria. The effects of this combination therapy on the pharmacokinetic disposition of CQ is, however, unpredictable. A standard treatment with 25 mg CQ base per kg